Biofrontera Inc
Change company Symbol lookup
Select an option...
BFRI Biofrontera Inc
LITE Lumentum Holdings Inc
TMAC Music Acquisition Corp
AFL Aflac Inc
IGC India Globalization Capital Inc
KSM DWS Strategic Municipal Income Trust
CNC Centene Corp
WPM Wheaton Precious Metals Corp
HPX^ HPX Corp
KRNLU Kernel Group Holdings Inc
Go

Company profile

Biofrontera Inc is a biopharmaceutical company. The Company is specialized in the commercialization of pharmaceutical products for the treatment of dermatological conditions for the diseases caused primarily by exposure to sunlight that result in sun damage to the skin. Its products focus on the treatment of actinic keratoses, which are skin lesions that lead to skin cancer. It also markets a topical antibiotic for treatment of impetigo, a bacterial skin infection. The Company’s principal product is Ameluz, which is a prescription drug for use in combination with its medical device, the BF-RhodoLED lamp, for photodynamic therapy (PDT) in the United States for the lesion-directed and field-directed treatment of actinic keratosis of mild-to-moderate severity on the face and scalp. It offers Xepi for the treatment of impetigo, a common skin infection, due to Staphylococcus aureus or streptococcus pyogenes.

Price
Delayed
$5.20
Day's Change
0.87 (20.09%)
Bid
--
Ask
--
B/A Size
--
Day's High
6.58
Day's Low
4.23
Volume
(Heavy Day)

Today's volume of 71,439,943 shares is on pace to be much greater than BFRI's 10-day average volume of 42,029,659 shares.

71,439,943

Company Profile

Biofrontera Inc is a biopharmaceutical company. The Company is specialized in the commercialization of pharmaceutical products for the treatment of dermatological conditions for the diseases caused primarily by exposure to sunlight that result in sun damage to the skin. Its products focus on the treatment of actinic keratoses, which are skin lesions that lead to skin cancer. It also markets a topical antibiotic for treatment of impetigo, a bacterial skin infection. The Company’s principal product is Ameluz, which is a prescription drug for use in combination with its medical device, the BF-RhodoLED lamp, for photodynamic therapy (PDT) in the United States for the lesion-directed and field-directed treatment of actinic keratosis of mild-to-moderate severity on the face and scalp. It offers Xepi for the treatment of impetigo, a common skin infection, due to Staphylococcus aureus or streptococcus pyogenes.

Valuation Ratios

Price/Earnings (TTM)
--
Price/Sales (TTM)
3.66x
Price/Book (MRQ)
20.89x
Price/Cash Flow (TTM)
--
TTM = Trailing Twelve Months
MRQ = Most Recent Quarter

Price Performance

Historic Growth and Share Detail

Historic Growth

No historic growth available.

Short Interest

November 2021
Current Month
199.9K
Previous Month
0
Percent of Float
5.55%
Days to Cover
0.0952 Days

Share Information

BFRI is in a share class of common stock
Float
3.6M
Shares Outstanding
11.6M
Institutions Holding Shares
--
--

Financial Statements

Balance sheet

Values displayed are in thousands.

Income statement

Values displayed are in thousands.

Cash flow

Values displayed are in thousands.

Company Officers

No company officers listed.

Address

Insider Trading

No insider trading activity.

Market data accompanied by is delayed by at least 15 minutes for NASDAQ, NYSE MKT, NYSE, and options. Duration of the delay for other exchanges varies.
Market data and information provided by Morningstar.

Insider trading information report provided by Copyright © 2021. All rights reserved.

Reuters content is the intellectual property of Reuters. Any copying, republication or redistribution of Reuters content, including by caching, framing or similar means, is expressly prohibited without the prior written consent of Reuters. Reuters is not liable for any errors or delays in content, or for any actions taken in reliance on any content. Reuters, Reuters Logo and the Sphere Logo are trademarks and registered trademarks of the Reuters Group of companies around the world.

Data is provided for information purposes only and is not intended for trading purposes. Reuters shall not be liable for any errors or delay in the content, or for any action taken in reliance on any content. The RIC or Reuters Instrument Code set has been developed and maintained by Reuters and is the intellectual property of Reuters.